Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 2

06:32 EDT 21st June 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 26–50 of 6,400+

Relevant

Summit Therapeutics plc: Summit Therapeutics Files US Annual Report on Form 20F

Summit Therapeutics plc ('Summit', or the 'Company')Summit Therapeutics Files US Annual Report on Form 20-FOxford, UK, and Cambridge, MA, US, 13 April 2018 - Summit Therapeutics plc (AIM: SUMM, NA...


Nasdaq Stockholm AB: Observationsnoteringen för Wilson Therapeutics AB uppdateras / The observation status for Wilson Therapeutics AB is updated (89/18)

Den 11 april 2018 observationsnoterades aktierna i Wilson Therapeutics AB ("Bolaget") med hänvisning till ett offentligt uppköpserbjudande från Alexion Pharmaceuticals Inc., genom dess dotterbolag ...

Abeona Therapeutics Inc: Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

NEW YORK and CLEVELAND, 2018-02-02 14:45 CET (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...


Novartis teams up with Pear Therapeutics to develop digital therapeutics for schizophrenia, MS

Pear Therapeutics Chief Medical Officer Yuri Maricich emphasized that the products Pear is developing with Novartis are intended to do more than support adherence. 

Trillium Therapeutics Inc.: Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

TORONTO, ONTARIO -- (Marketwired) -- 02/09/18 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of ...

Celsius Therapeutics Launches with $65M to Develop Precision Therapeutics for Autoimmune Disease & Cancer

Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of...

Probably Relevant

CureVac and Arcturus Collaborate to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

TÜBINGEN, Germany & BOSTON & SAN DIEGO–(BUSINESS WIRE)–CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messe...

Summit Therapeutics plc: Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference

Summit Therapeutics plc('Summit', or the 'Company')SUMMIT THERAPEUTICS TO PARTICIPATE IN 2018 BTIG HEALTHCARE CONFERENCEOxford, UK, 23 February 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: S...

Spark Therapeutics, Inc.: Spark Therapeutics nimmt an mehreren Konferenzen im Januar teil

PHILADELPHIA (USA), 3. Januar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar...

AdoRx raises $10m for new cancer therapeutics

UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.

Summit Therapeutics plc: Result of AGM

Summit Therapeutics plc ('Summit' or the 'Company')Result of Annual General MeetingOxford, UK, and Cambridge, MA, US, 7 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that...

Knight Therapeutics Inc. and SIFI S.p.A: Knight Therapeutics and SIFI S.p.A. Announce Filing of New Drug Submission for NETILDEX in Canada

MONTREAL, QUEBEC -- (Marketwired) -- 02/15/18 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and S.I.F.I- Societa Industria Farmaceutica Ita...

Sandoz and Pear to create digital therapeutics for opioid use disorders

Novartis has signed an agreement with Pear Therapeutics to develop and commercialise prescription digital therapeutics for patients with substance and...Read More... The post Sandoz and Pear to create digital therapeutics for opioid use disorders appeared first on Pharmaceutical Technology.

M&As this week: United Therapeutics, Par Formulations, Endo Ventures

United Therapeutics Corporation has agreed to acquire SteadyMed for $216m. United Therapeutics will purchase SteadyMed for $4.46 a share in...Read More... The post M&As this week: United Therapeutics, Par Formulations, Endo Ventures appeared first on Pharmaceutical Technology.

SalvaRX sees 'substantial progress' as investees score patent protection

Drug development company SalvaRX Group offered a business update on Thursday, confirming significant progress for investees iOx Therapeutics and Intensity Therapeutics. iOsx Therapeutics, in which ...

Abeona Therapeutics Inc: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights

Investor Conference Call on Monday, May 14th at 10:00 am ET NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceuti...

CRISPR Therapeutics’ Lundberg Steps Down as Chief Scientific Officer

Bill Lundberg is leaving his position as chief scientific officer of CRISPR Therapeutics (NASDAQ: CRSP). CRISPR Therapeutics, which has operations in Switzerland and Cambridge, MA, said that Lundberg will continue as an advisor to the company and he is now head of its scientific advisory board. CRISPR Therapeutics develops treatments based on the CRISPR-Cas9 gene […]

Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline

Alexion Pharmaceuticals is buying Wilson Therapeutics for $855 million. With the company, Alexion will acquire WTX101, Wilson Therapeutics’ Phase III compound for Wilson disease.

Abeona Therapeutics Inc: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharma...

Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics

NewsThe companies have entered into a license agreement regarding a collaborative licensing, research, and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Centogene, Aldeyra to advance therapeutics for SLS patients

Centogene has signed an agreement with Aldeyra Therapeutics for the advancement of novel therapeutics for patients with Sjögren-Larsson Syndrome (SLS).

Quotidian Technical Highlights on Selected Biotech Stocks -- Voyager Therapeutics, Cambrex, ...

www.wallstequities.com/registration Voyager Therapeutics Cambridge, Massachusettsheadquartered Voyager Therapeutics Inc.'s shares recorded a trading volume of 212,557 shares last Friday. The stock finished the trading session Read more...

Active-Investors: Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital

LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) ("InVivo Therapeutics"). If you want ...

Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

To treat demyelinating and degenerative diseases of the CNS

Sandoz targets digital therapeutics

Partners with Pear Therapeutics to launch FDA-approved apps


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks